Child and Adolescent Psychiatry, Regional Hospital Bozen, Bolzano, Italy.
Nat Prod Res. 2010 Feb;24(3):203-5. doi: 10.1080/14786410802076259.
There is evidence for the efficacy of noradrenaline and serotonin reuptake inhibitors treating attention-deficit hyperactivity disorder (ADHD). In this open trial, we checked St. John's wort, a serotonin and noradrealine reuptake inhibitor, and actually used as an antidepressant, for this indication. Three 14-16-year-old male psychiatric outpatients, diagnosed with ADHD have been rated at baseline and while taking St. John's wort or a placebo, respectively, by the Conner Scale and by the Continuous Performance Test, to determine its efficacy as a treatment option for ADHD. Patients' mean scores improved for Conners' hyperactivity, inattention and immaturity factors. Although the sample size is very small and therefore generalisation is very difficult, this observation indicates that St. John's wort might be a slightly effective treatment for ADHD also.
有证据表明去甲肾上腺素和 5-羟色胺再摄取抑制剂可有效治疗注意力缺陷多动障碍(ADHD)。在本次开放性试验中,我们针对这种适应证,对圣约翰草(一种 5-羟色胺和去甲肾上腺素再摄取抑制剂,实际上被用作抗抑郁药)进行了检验。三名 14-16 岁的男性精神科门诊患者,被诊断为 ADHD,分别在基线时和服用圣约翰草或安慰剂时,通过 Conner 量表和连续操作测试进行了评估,以确定其作为 ADHD 治疗选择的疗效。患者的康纳多动、注意力不集中和不成熟因子的平均分均有所提高。尽管样本量非常小,因此很难推广,但这一观察结果表明,圣约翰草可能对 ADHD 也有一定的治疗效果。